Today's Date: March 26, 2023
National University Receives 2023 Military Friendly® Gold Designation   •   Philadelphia Works Names First Female Chief Operating Officer   •   HYZON MOTORS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers   •   DISH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against DISH Network Corporatio   •   ARGO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Argo B   •   Statement from the Chief Public Health Officer of Canada on World TB Day   •   SAMARITAN'S PURSE RUSHING HELP TO FAMILIES IMPACTED BY DEADLY TORNADOES IN MISSISSIPPI   •   Jennifer S. Wilkov Finalizes Lineup for the 2023 April Speak Up Women Conference   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Stanley Black & Decker, Inc. with Losses of $100,000 t   •   Here Comes Bunnysaurus Rex Hopping Down the Dinosaur Trail   •   SBNY LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Signature Bank Investors to Secure Counsel Before Important D   •   Build community with shared future, create better world   •   Early Education Leadership Conference in Hershey Brings Together Hundreds of Child Advocates   •   Atlanta Housing, Residents Celebrate 102nd Birthday of Clara "Mama" Bridges   •   SOTERA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sote   •   ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting   •   SOTERA HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Los   •   GINKGO BIOWORKS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Office   •   NATIONAL VISION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Aga   •   Korelya Capital Invests in Weo, Bringing Total Funds Raised to $15M, and Leads Launch of its Series A Financing Round
Bookmark and Share

Dr. Andi Grant is appointed to CEO at BioOra

Dr. Andi Grant is appointed to CEO at BioOra

PR Newswire

MIAMI and WELLINGTON, New Zealand, Feb. 2, 2023 /PRNewswire/ -- BioOra Limited, a Bridgewest Group portfolio company, appoints new CEO, Dr. Andi Grant.  Dr. Grant has an accomplished career in global pharmaceutical and biotech businesses, driving the development and commercialization of medical innovations.  Her operational and strategic business experience has been forged through leadership roles at Incyte and Galapagos, both during early stages and transitioning to fully integrated pharmaceutical companies.  As CEO and Managing Director of Living Cell Technologies, Andi led the company in creating a safe, quality and consistent manufacturing process to produce end products used in patients.

"BioOra is on the frontier of developing therapies that will change lives."

"We are excited to welcome Andi to BioOra," said Dr. Peter Crabtree, Chairman of BioOra. "Andi is a proven value creator and vastly experienced leader who knows how to bring novel products to market.  Throughout her career, Andi has gravitated to companies who are pioneers at the forefront of medical innovation," added Dr. Crabtree.

"There is no question that BioOra is on the frontier of developing therapies that will change lives," says Dr. Grant. "Through the deep industry experience and support of Bridgewest Group, together with our partnership with Malaghan Institute, we will build on, automate and commercialize the initial research," added Dr. Grant.

Mike Zablocki, General Manager of the Malaghan Institute of Medical Research, New Zealand's leading independent biomedical research organization is partnering with BioOra on the clinical development of its CAR-T cell therapy.  "In partnership with Dr. Grant and her team, our immediate focus will be to finalize the automation of CAR-T cell therapy manufacturing, to allow us to extend the benefits of this breakthrough treatment as widely as possible," said Zablocki.

"There is enormous potential to improve patient's lives with personalized medicines.  Our goal is to create a global leader in the automated manufacture of personalized cell therapies and end to end patient delivery. This is eminently achievable with the IP that has already been established.  I am honored to join BioOra and to lead the team on this remarkable journey," said Dr. Grant.

Dr. Grant holds a PhD in molecular neurobiology from the University of Cambridge, UK.

About Bridgewest Group

Bridgewest Group is an innovative and privately held global investment firm with over $3B in private capital.  Founded in 1999, the global firm has earned a long-standing reputation for creating and scaling transformational businesses to achieve outsized success. Bridgewest Group leverages its expertise and global eco-community in key sectors where it can have the greatest impact including Biotech, Software, Semiconductor and Artificial Intelligence/Deep Tech.  Customized financial investment services and diverse real estate holdings augment equity assets and support portfolio companies as they grow.  Bridgewest Group is based in the US, with investments primarily in the US, Europe, China and Australasia.

About Bridgewest Ventures 

Bridgewest Ventures NZ LP is part of the Bridgewest Group, a US-based investment company, that is recognized for its ability to successfully incubate and launch major global innovation-led companies.  Bridgewest Ventures utilizes the same successful model in New Zealand.  It leverages the connections, international reach, and commercialization experience of Bridgewest Group to transform New Zealand opportunities into world-class companies.

Bridgewest Ventures NZ LP is an approved partner of the Callaghan Innovation Technology Incubator Programme. Callaghan Technology Incubator provides additional details for the Technology Incubator programme.

About BioOra

BioOra is pioneering medical innovation through automated personalized cell therapies.  It is the only licensed GMP contract and development therapeutics manufacturer of CAR-T cell therapeutics in New Zealand.  In partnership with Bridgewest Ventures and the Malaghan Institute of Medical Research, BioOra is developing novel automated manufacturing of CAR-T cell immunotherapy, to help deliver life-saving immunotherapies efficiently and affordably to patients around the globe.

About The Malaghan Institute

The Malaghan Institute of Medical Research is New Zealand's leading independent biomedical research institute with a focus on immunology and immunotherapy and a long history of personalised cell therapy.  The institute is working in partnership with Wellington Zhaotai Therapies to trial a third generation CAR-T cell therapy in New Zealand for patients with relapsed and refractory B-cell non-Hodgkin lymphoma.  BioOra is working with the Malaghan Institute to automate the production of CAR-T cells and similar treatments.

Media Contact: Jenny Bourbiel,

Cision View original content to download multimedia:

SOURCE Bridgewest Capital Management LLC

Back to top
| Back to home page

White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News